| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4de36eaaa471d491a1c3f2ae25eaef97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf2c54d5a3e3f639740ecbfbb72fd4b4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2018-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0be3fc3f5e3fbc82a0ac1ca6da4519e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1758135c00fd09e941ca627242676f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5290dc2f2859321e64d5f9671a7d313
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b8313517cf72e7fd8cd5ad404cf8ec2 |
| publicationDate |
2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-122021012549-B8 |
| titleOfInvention |
ORAL MELATONIN DISSOLUTION COMPOSITION WITH ACIDIFYING AGENT THAT MAKES MELATONIN SOLUBLE IN SALIVA |
| abstract |
The present invention relates to a composition that includes a pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva for as long as the dosage form is dissolved therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in saliva within ten minutes of contact with saliva. |
| priorityDate |
2017-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |